Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting

600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
Thursday, October 21, 2010 - 10:00 a.m.

Welcome and Comments from DMAS' Director	**Gregg Pane, M.D.**
Comments from the Secretary of Health and Human Resources	**The Honorable William Hazel, M.D.**
Call to Order	**Randy Axelrod, M.D., Chairman**
Drug Utilization Review (DUR) Board Update	**Avtar Dhillon, MD, DMAS DUR Board**
Provider Synergies Services Update	**Debbie Moody, Clinical Manager**
Approval of Minutes From April 29, 2010 Meeting	**P&T Committee Members**
PDL Management	**P&T Committee Members**

- **Old Business**
  - Utilization of Soma®
  - Utilization of Risperadone in Children under the Age of 6
  - Utilization of Quetiapine (Seroquel®) in Children under the Age of 6
  - AAP's Guidelines for the Use of Cough and Cold Products in Children

- **PDL Phase II – New Drug Review (Therapeutic Class)**
  - Cambia™ and naratriptan (Antimigraine Agents formally Serotonin Receptor Agonists)
  - Differin® 0.1% Lotion, adapalene 0.1% gel and cream (Topical Retinoids/Combinations)
  - Exalgo™ (Long Acting Narcotics)
  - Methylphenidate oral solution and methamphetamine (ADHD Products)
  - Pennsaid® (Topical Agents and Anesthetics)
  - Xerese™ (Topical Antivirals)
  - Zipsor™ and Vimovo™ (NSAIDs including COX-2 Inhibitors)
  - Zymaxid™ (Ophthalmic Quinolones)

- **PDL Phase I – Annual Review**
  - ***Antivirals***
    - Hepatitis C
  - ***Cardiac Medications***
    - Angiotensin Modulators
      - Angiotensin-Converting Enzyme Inhibitors (includes combination products)
      - Angiotensin II Receptor Antagonists (includes combination products)
      - Direct Renin Inhibitors (including combination product)
    - Anticoagulants, Injectable
      - Low Molecular Weight Heparins
      - Factor Xa Inhibitor
    - Beta Blockers
    - Calcium Channel Blockers (includes dihydropyridine & non-dihydropyridine agents)
    - Lipotropics
      - Statins (includes combinations with niacin, CAI agent, CCBs)
      - Other (includes Fibric Acid derivatives, Omega 3 fatty acid, Niacin, Bile Acid Sequestrants and CAI agent)

- **PDL Phase I – Annual Review / Cardiac Medications (continued)**
  - Pulmonary Arterial Hypertension (PAH) Agents (formally PDE-5 Inhibitors – pulmonary hypertension)
    - PDE-5 Inhibitors
    - Potential new products to be reviewed for possible inclusion
      - Endothelin-1 agents including Letairis® and Tracleer®
      - prostacyclin analogues including Tyvaso™ and Ventavis®
- ***Central Nervous System***
  - Sedative Hypnotics
  - Other Hypnotics
- ***Endocrine & Metabolic Agents***
  - Growth Hormones
  - Erythropoiesis Stimulating Proteins (formerly Hematopoietic Agents)
  - Progestins for Cachexia
- ***Gastrointestinal***
  - Histamine-2 Receptor Antagonists
  - Proton Pump Inhibitors
  - Ulcerative Colitis (oral and rectal)
- ***Genitourinary***
  - Bladder Relaxants (formerly Urinary Antispasmodics)
  - BPH Agents
    - Alpha Blockers for BPH
    - Androgen Hormone Inhibitors
  - Phosphate Binders (formerly Electrolyte Depleters)
- ***Immunologic Agents***
  - Topical Immunomodulators
- ***Respiratory***
  - Antihistamines – 2nd generation (includes combination products)
  - Bronchodilators, Beta Adrenergic
    - Short Acting
    - Long Acting
  - Bronchodilators, Anticholinergic
  - Intranasal Rhinitis Agents
    - Intranasal Steroids
    - Intranasal Antihistamines (this was previously in the Spring review)
    - Intranasal Anticholingerics
  - Inhaled Corticosteroids
  - Self-Injectable Epinephrine

Confidential Meeting ♦ **Pricing Information Discussion**	**P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8**
PDL Recommendations and Vote	**P&T Committee Members**
Criteria Discussion of Phase II New Drugs**	**P&T Committee Members**
Criteria Discussion of PDL Phase I Drug Classes**	**P&T Committee Members**
Next Meeting – January, 2011	**Randy Axelrod, M.D., Chairman**

***Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Review – October 2009 to present
- New Drugs in PDL Phase II Drug Classes – October 2008 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov **by close of business on Friday, September 24, 2010.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov **by close of business on Friday, September 24, 2010.**